Literature DB >> 12162928

Migraine Headache: Immunosuppressant Therapy.

Todd D. Rozen1.   

Abstract

There is very little literature on the use of immunosuppressant drugs in migraine treatment. Immunosuppressive agents are rarely, if ever, used as regular abortive drugs for episodic migraine attacks, and are never used as migraine preventives, because of the risk of side effects that come along with prolonged usage. Immunosuppressant drugs have been used in the emergency room as treatment for severe migraine attacks (intravenous corticosteroids), in the treatment of sustained or status migraine (oral or intravenous corticosteroids), in the treatment of drug-overuse headache (oral or intravenous corticosteroids), and in the treatment of immunosuppressant-induced headache in organ transplant recipients. Corticosteroids are commonly used as therapy for status migraine. Short courses of rapidly tapering doses of oral corticosteroids (prednisone or dexamethasone) can alleviate status migraine. Intravenous corticosteroids (methylprednisolone) in a single dose (emergency room or outpatient infusion unit) or as several days of repetitive dosing (in-hospital strategy) can be used to break long-lasting migraine attacks. A new use for corticosteroids in migraine therapy is to treat drug-overuse headache. Patients with drug-overuse or "rebound" headache will only improve once their symptomatic medications have been discontinued. Stopping "rebounding medications" in the short-term can lead to withdrawal symptoms and a worsening of headache. In the long-term, it will lead to headache improvement. There are both outpatient and inpatient treatment strategies to detoxify patients off of misused medications. Corticosteroids have been used in the management of headache during the detoxification process as both outpatient treatments using short courses of oral corticosteroids or as repetitive intravenous therapy in an inpatient setting. Headache is a well-recognized but poorly reported side effect of organ transplantation. The approach to headache evaluation and management in the transplant setting is unique. Physicians must investigate all possible causes of headache from benign side effects of medications to precursors of potentially catastrophic neurologic abnormalities. One needs to think in terms of pharmacologic versus nonpharmacologic causes of headache. Immunosuppressive agents commonly known to cause headache include cyclosporine, tacrolimus (FK506), and muromonab CD3 (OKT3).

Entities:  

Year:  2002        PMID: 12162928     DOI: 10.1007/s11940-002-0050-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  12 in total

1.  The side effects of FK 506 in humans.

Authors:  R Shapiro; J J Fung; A B Jain; P Parks; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Neurological disorders in liver and kidney transplant recipients.

Authors:  W Christe
Journal:  Transplant Proc       Date:  1994-12       Impact factor: 1.066

3.  Treatment-refractory cyclosporine-associated headache: relief with conversion to FK-506.

Authors:  T D Rozen; E F Wijdicks; J E Hay
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

4.  Emergency treatment of intractable migraine.

Authors:  R M Gallagher
Journal:  Headache       Date:  1986-02       Impact factor: 5.887

Review 5.  Basic mechanisms in vascular headache.

Authors:  M A Moskowitz
Journal:  Neurol Clin       Date:  1990-11       Impact factor: 3.806

6.  Cyclosporin associated headache.

Authors:  M J Steiger; T Farrah; K Rolles; P Harvey; A K Burroughs
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-10       Impact factor: 10.154

7.  Abortive migraine therapy in the office with dexamethasone and prochlorperazine.

Authors:  H A Saadah
Journal:  Headache       Date:  1994-06       Impact factor: 5.887

8.  Management of acute intractable headaches using i.v. therapy in an office setting.

Authors:  J Stiller
Journal:  Headache       Date:  1992-11       Impact factor: 5.887

9.  Propranolol for the treatment of cyclosporine-induced headaches.

Authors:  J Gryn; J Goldberg; E Viner
Journal:  Bone Marrow Transplant       Date:  1992-03       Impact factor: 5.483

10.  Amitriptyline and dexamethasone combined treatment in drug-induced headache.

Authors:  U Bonuccelli; A Nuti; C Lucetti; N Pavese; G Dell'Agnello; A Muratorio
Journal:  Cephalalgia       Date:  1996-05       Impact factor: 6.292

View more
  5 in total

Review 1.  Hints on Diagnosing and Treating Headache.

Authors:  Arne May
Journal:  Dtsch Arztebl Int       Date:  2018-04-27       Impact factor: 5.594

2.  Spinal Stroke following Kidney Transplant.

Authors:  Jayanthan B Subramanian; Farjad Siddiqui; Pranit N Chotai; Yazan Al-Adwan; Amer Rajab; Kenneth Washburn; Austin D Schenk; Ashley J Limkemann; Michael Luttrull; Musab Al-Ebrahim; Ginny Bumgardner; Navdeep Singh
Journal:  Case Rep Transplant       Date:  2022-05-21

3.  Headache in the first manifestation of Multiple Sclerosis - Prospective, multicenter study.

Authors:  Marcel Gebhardt; Peter Kropp; Tim P Jürgens; Frank Hoffmann; Uwe K Zettl
Journal:  Brain Behav       Date:  2017-11-16       Impact factor: 2.708

4.  Post-infectious new daily persistent headache may respond to intravenous methylprednisolone.

Authors:  Sanjay Prakash; Nilima D Shah
Journal:  J Headache Pain       Date:  2010-02       Impact factor: 7.277

Review 5.  Intravenous treatment of chronic daily headaches in the outpatient headache clinic.

Authors:  John Claude Krusz
Journal:  Curr Pain Headache Rep       Date:  2006-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.